US4911690A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment or diagnosis by endoscopic administration into the lymphatics
Assignee: United States Department of Health and Human Services
•
Filing: 1988-12-17
•
Granted: 1990-03-27
•
Expires: 2008-12-17
Abstract
Abstract The invention provides a method of delivering therapeutic or diagnostic reagents to the lymphatic system. In the preferred method the delivery is accomplished by use of a fiberoptic endoscope equipped with an aspiration cytology needle. The method provides an especially useful means of delivering labeled monoclonal antibodies.
Inventors
- 👤 James L. Mulshine
- 👤 John Weinstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 04:11
CPC Classifications
A; A61; A61M; A61M31/00; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/12; A61K51/1282; A61K2121/00; A61K2123/00
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
42 words
A process for delivering therapeutric or diagnostic reagents directly to the lymphatics comprising the steps of: (1) inserting an endoscope into a body passage or cavity, and (2) administering the reagent through the endoscope into tissues for uptake by the lymphatic vessels.
Claim 2
Dependent Claim
42 words
A process for delivering therapeutric or diagnostic reagents directly to the lymphatics comprising the steps of: (1) inserting an endoscope into a body passage or cavity, and (2) administering the reagent through the endoscope into tissues for uptake by the lymphatic vessels.
Claim 3
Dependent Claim
65 words
A process according to claim 1 for delivering a composition containing therapeutic and/or diagnostic reagents to tissues for uptake by lymphatic vessles comprising the steps of: (1) inserting an endoscope into a body passage or cavity in the location of tissues near the terminal lymphatic vessels, and (2) administering the composition by injection into tissues in the area of the terminus of the lymphatic vessels.
Claim 4
Dependent Claim
13 words
A process according to claim 2 wherein the endoscope is a fiberoptic bronchoscope.
Claim 5
Dependent Claim
18 words
A process according to claim 3 wherein the injection is accomplished by use of an aspiration cytology needle.
Claim 6
Dependent Claim
13 words
A process according to claim 2 wherein the injectate contains a monoclonal antibody.
Claim 7
Dependent Claim
13 words
A process according to claim 5 wherein the antibody is a radiolabeled antibody.
Claim 8
Dependent Claim
13 words
A process according to claim 4 wherein the injectate contains a monoclonal antibody.
Claim 9
Dependent Claim
14 words
A process according to claim 2 wherein the composition comprises an antigastrum-releasing peptide antibody.
Claim 10
Dependent Claim
14 words
A process according to claim 1 wherein the reagent is delivered as an aerosol.
Claim 11
Dependent Claim
13 words
A process according to claim 1 wherein the reagent is an antibody conjugate.
Claim 12
Dependent Claim
13 words
A process according to claim 2 wherein the composition contains an antibody conjugate.
Claim 13
Dependent Claim
14 words
A process according to claim 10 wherein the antibody is conjugated to a cytotoxin.
Claim 14
Dependent Claim
14 words
A process according to claim 11 wherein the antibody is conjugated to a cytotoxin.
Claim 15
Dependent Claim
15 words
A process according to claim 10 wherein the antibody is conjugated to a differentiation agent.
Claim 16
Dependent Claim
15 words
A process according to claim 11 wherein the antibody is conjugated to a differentiation agent.
Claim 17
Dependent Claim
14 words
A process according to claim 10 wherein the antibody is conjugated to an immunotoxin.
Claim 18
Dependent Claim
14 words
A process according to claim 11 wherein the antibody is conjugated to an immunotoxin.
Claim 19
Dependent Claim
14 words
A process according to claim 10 wherein the antibody is conjugated to a radionucleotide.
Claim 20
Dependent Claim
14 words
A process according to claim 11 wherein the antibody is conjugated to a radionucleotide.
Claim 21
Dependent Claim
13 words
A process according to claim 1 wherein the reagent contains an immunoglobulin fragment.
Claim 22
Dependent Claim
13 words
A process according to claim 2 wherein the composition contains an immunoglobulin fragment.
Claim 23
Dependent Claim
18 words
A process according to claim 1 wherein the reagent contains a genetically engineered derivative of an immunoglobulin molecule.
Claim 24
Dependent Claim
18 words
A process according to claim 2 wherein the composition contains a genetically engineered derivative of an immunoglobulin molecule.
References Cited (Backward Citations)
US3927660A
Cited
US4714460A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-26 | 1993-09-25 | 1994-03-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-26 | 1997-09-25 | 1998-03-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-26 | 2001-09-25 | 2002-03-27 | $7700.00 | Window Closed / Lapsed |